Ranibizumab versus bevacizumab for ophthalmic diseases related to neovascularisation: A meta-analysis of randomised controlled trials

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Wu, Bin ^a   Wu, Haixiang ^b   Liu, Xiaoyan ^a   Lin, Houwen ^a   Li, Jin ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; MONOCLONAL ANTIBODY;

ARTERY THROMBOSIS; ARTICLE; DATA ANALYSIS; DIABETIC MACULAR EDEMA; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; EYE DISEASE; HEALTH CARE COST; HUMAN; META ANALYSIS; MYOPIA; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGIC MYOPIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA ANGIOMATOUS PROLIFERATION; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RISK ASSESSMENT; SYSTEMATIC REVIEW; SYSTEMIC DISEASE; THROMBOEMBOLISM; TREATMENT OUTCOME; VISUAL ACUITY; CHOROIDAL NEOVASCULARIZATION; COMPARATIVE STUDY; EYE DISEASES; RETINAL NEOVASCULARIZATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; EYE DISEASES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETINAL NEOVASCULARIZATION; VISUAL ACUITY;

EID: 84903739988     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101253     Document Type: Article

References (42)

1. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31.
2. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407: 249-257.
3. Shams N, Ianchulev T (2006) Role of vascular endothelial growth factor in ocular angiogenesis. Ophthalmol Clin North Am 19: 335-344. (Pubitemid 44279356)
4. Dixon JA, Oliver SC, Olson JL, Mandava N (2009) VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs 18: 1573-1580.
5. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, et al. (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57: 4593-4599. (Pubitemid 27441066)
6. McCartney M (2011) Off-label prescribing in macular degeneration. BMJ 343: d6778.
7. Brechner RJ, Rosenfeld PJ, Babish JD, Caplan S (2011) Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file. Am J Ophthalmol 151: 887-895 e881.
8. Ferrara N, Damico L, Shams N, Lowman H, Kim R (2006) Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26: 859-870. (Pubitemid 44547437)
9. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, et al. (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 116: 57-65 e55.
10. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, et al. (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419-1431. (Pubitemid 44511557)
11. Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, et al. (2012) A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard. PLoS One 7: e42701.
12. Banfi R, Attanasio F, Palazzi N, Colombini S, Falai T, et al. (2013) Bevacizumab versus ranibizumab: why are we not playing the joker? Int J Clin Pharm 35: 507-509.
13. Group CR, Martin DF, Maguire MG, Ying GS, Grunwald JE, et al. 2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364: 1897-1908.
14. Comparison of Age-related Macular Degeneration Treatments Trials Research G, Martin DF, Maguire MG, Fine SL, Ying GS, et al. (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119: 1388-1398.
15. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, et al. (2013) Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 382: 1258-1267.
16. Krebs I, Schmetterer L, Boltz A, Told R, Vecsei-Marlovits V, et al. (2013) A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol 97: 266-271.
17. Kodjikian L, Souied EH, Mimoun G, Mauget-Faysse M, Behar-Cohen F, et al. (2013) Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Ophthalmology 120: 2300-2309.
18. Subramanian ML, Abedi G, Ness S, Ahmed E, Fenberg M, et al. (2010) Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. Eye (Lond) 24: 1708-1715.
19. Gharbiya M, Giustolisi R, Allievi F, Fantozzi N, Mazzeo L, et al. (2010) Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab-a randomized controlled trial. Am J Ophthalmol 149: 458-464 e451.
20. Iacono P, Parodi MB, Papayannis A, Kontadakis S, Sheth S, et al. (2012) Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization. Retina 32: 1539-1546.
21. Parodi MB, Iacono P, Menchini F, Sheth S, Polini G, et al. (2013) Intravitreal bevacizumab versus ranibizumab for the treatment of retinal angiomatous proliferation. Acta Ophthalmol 91: 267-273.
22. Nepomuceno AB, Takaki E, Paes de Almeida FP, Peroni R, Cardillo JA, et al. (2013) A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. Am J Ophthalmol 156: 502-510 e502.
23. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097.
24. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12. (Pubitemid 26120810)
25. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560. (Pubitemid 37088507)
26. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558. (Pubitemid 34746062)
27. Egger M, Smith GD (1998) Bias in location and selection of studies. BMJ 316: 61-66.
28. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
29. Kim JH, Seo HW, Han HC, Lee JH, Choi SK, et al. (2013) The effect of bevacizumab versus ranibizumab in the treatment of corneal neovascularization: a preliminary study. Korean J Ophthalmol 27: 235-242.
30. Anti-VEGF therapy for the treatment of glaucoma: a focus on ranibizumab and bevacizumabLi J, Zhang H, Sun P, Gu F, Liu ZL (2013) Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients. Int J Ophthalmol 6: 169-173.
31. Park SC, Su D, Tello C (2012) Anti-VEGF therapy for the treatment of glaucoma: a focus on ranibizumab and bevacizumab. Expert Opin Biol Ther 12: 1641-1647.
32. Cho HJ, Baek JS, Lee DW, Kim CG, Kim JW (2012) Short-term effectiveness of intravitreal bevacizumab vs. ranibizumab injections for patients with polypoidal choroidal vasculopathy. Korean J Ophthalmol 26: 157-162.
33. Hufendiek K, Hufendiek K, Panagakis G, Helbig H, Gamulescu MA (2012) Visual and morphological outcomes of bevacizumab (Avastin(R)) versus ranibizumab (Lucentis(R)) treatment for retinal angiomatous proliferation. Int Ophthalmol 32: 259-268.
34. Cho HJ, Kim JW, Lee DW, Cho SW, Kim CG (2012) Intravitreal bevacizumab and ranibizumab injections for patients with polypoidal choroidal vasculopathy. Eye (Lond) 26: 426-433.
35. Ozturk BT, Kerimoglu H, Bozkurt B, Okudan S (2011) Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema. J Ocul Pharmacol Ther 27: 373-377.
36. Ford JA, Elders A, Shyangdan D, Royle P, Waugh N (2012) The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review. BMJ 345: e5182.
37. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, et al. (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99: 1232-1239. (Pubitemid 47299901)
38. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S (2008) Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300: 2277-2285.
39. Cheng JW, Cheng SW, Lu GC, Wei RL (2012) Effect of intravitreal antivascular endothelial growth factor therapy on the risk of arterial thromboembolic events: a meta-analysis. PLoS One 7: e41325.
40. Curtis LH, Hammill BG, Schulman KA, Cousins SW (2010) Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 128: 1273-1279.
41. van der Reis MI, La Heij EC, De Jong-Hesse Y, Ringens PJ, Hendrikse F, et al. (2011) A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina 31: 1449-1469.
42. Chen XL, Lei YH, Liu CF, Yang QF, Zuo PY, et al. (2013) Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysis. PLoS One 8: e66721.